The CD95 (apo-1/fas) system mediates drug-induced apoptosis in neuroblastoma cells

Cancer Research

Volumn 57, Issue 17, 1997, Pages 3823-3829

  Fulda, Simone ^a   Sieverts, Hauke ^a   Friesen, Claudia ^a   Herr, Ingrid ^a   Debatin, Klaus Michael ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOSPORIN A; DOXORUBICIN; ETOPOSIDE; FAS ANTIGEN; INTERLEUKIN 1BETA CONVERTING ENZYME;

APOPTOSIS; ARTICLE; CELL DEATH; CHEMOSENSITIVITY; CROSS RESISTANCE; CYTOTOXICITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; NEUROBLASTOMA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; CYCLOSPORINE; CYSTEINE ENDOPEPTIDASES; DNA FRAGMENTATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; ETOPOSIDE; FAS LIGAND PROTEIN; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE GLYCOPROTEINS; NEUROBLASTOMA; RNA, MESSENGER; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0030752603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Berthold, F. Overview: biology of neuroblastoma. In: C. Pochedly (ed.), Neuroblastoma: Tumor Biology and Therapy, pp. 1-30. Boca Raton, FL: CRC Press, 1990.
2. Pritchard, J., and Hickman J. A. Why does stage 4s neuroblastoma regress spontaneously? Lancet, 344: 869-870, 1994.
3. Oppenheim, R. W. Cell death during development of the nervous system. Annu. Rev. Neurosci., 14: 453-501, 1991.
4. Trauth, B. C., Klas, C., Peter, A. M. J., Matz, S., Möller, P., Falk, W., Debatin, K-M., and Krammer, P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science (Washington DC), 245: 301-305, 1989.
5. Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B., Ponstingl, H., and Krammer, P. H. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. J. Biol. Chem., 267: 10709-10715, 1992.
6. Nagata, S., and Golstein, P. The Fas death factor. Science (Washington DC), 267: 1449-1456, 1995.
7. Krammer, P. H., Dhein, J., Walczak, H., Behrmann, I., Mariani, S., Matiba, B., Fath, M., Daniel, P. T.,Knipping, E., Westendorp, M. O., Stricker, K., Baeumler, C., Hellbardt, S., Germer, M., Peter, M. E., and Debatin, K-M. The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev., 142: 175-191, 1994.
8. Debatin, K-M. Disturbances of the CD95 (APO-1/Fas) system in disorders of lymphohaematopoietic cells. Cell Death Differ., 3: 185-189, 1996.
9. Koizumi, H., Wakisaka, M., Nakada, K., Takakuwa, T., Fujioka, T., Yamate, N., and Uchikoshi, T. Demonstration of apoptosis in neuroblastoma and its relationship to tumor regression. Virchows Arch., 427: 167-173, 1995.
10. Suda, T., Takahashi, T., Golstein, P., and Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: 1169-1178, 1993.
11. Tanaka, M., Suda, T., Takahashi, T., and Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J., 14: 1129-1135, 1995.
12. Berthold, F., Burdach, S., Kremens, B., Lampert, F., Niethammer, D., Riehm, H., Ritter, J., Treuner, J., Utsch, S., and Zieschang, J. The role of chemotherapy in the treatment of children with neuroblastoma stage IV: the GPO (German Pediatric Oncology Society) experience. Klin. Paediatr., 202: 262-269, 1990.
13. Castleberry, R. P. Chemotherapy for neuroblastoma. In: C. Pochedly (ed.), Neuroblastoma: Tumor Biology and Therapy, pp. 305-317. Boca Raton, FL: CRC Press, 1990.
14. Doroshow, J. H. Anthracyclines and anthracenediones. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 409-434. Philadelphia: Lippincott-Raven, 1996.
15. Reed, E., Dabholkar, M., and Chabner, B. A. Platinum analogues. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 357-378. Philadelphia: Lippincott-Raven, 1996.
16. Pommier, Y., Fesen, M. R., and Goldwasser, F. Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives. In: B. A. Chabner and D. L. Longo (eds.), Cancer Chemotherapy and Biotherapy, pp. 435-461. Philadelphia: Lippincott-Raven, 1996.
17. Dive, C., and Hickman, J. A. Drug-target interactions: only the first step in the commitment to a programmed cell death? Br. J. Cancer, 64: 192-196, 1991.
18. Quillet-Mary, A., Mansat, V., Duchayne, E., Come, M. G., Allouche, M., Bailly, J. D., Bordier, C., and Laurent, G. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia (Baltimore), 10: 417-425, 1996.
19. Cece, R., Barajon, I., and Tredici, G. Cisplatin induces apoptosis in SH-SY5Y human neuroblastoma cell line. Anticancer Res., 15: 777-782, 1995.
20. L is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res., 55: 2576-2582, 1995.
21. Dole, M. G., Nunez, G., Merchant, A. K., Maybaum, J., Rode, C. K., Bloch, C. A., and Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblasloma. Cancer Res., 54: 3253-3259, 1994.
22. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
23. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
24. Dhein, J., Walczak, H., Baeumler, C., Debatin, K-M., and Krammer, P. H. Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature (Lond.), 373: 438-441, 1995.
25. Ross, R. A., Spengler, B. A., and Biedler, J. L. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. (Bethesda), 71: 741-745, 1983.
26. Schwab, M., Alitano, K., Klempnauer, K-H., Varmus, H. E., Bishop, J. M., Gilbert, F., Brodeur, G., Golstein, M., and Trent. J. Amplified DNA with limited homology to Myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumor. Nature (Lond.), 305: 245-248, 1983.
27. Seeger, R. C., Danon, Y. L., Rayner, S. A., and Hoover, F. Definition of a Thy-1 determinant of human neuroblastoma, glioma, sarcoma and teratoma cells with a monoclonal antibody. J. Immunol., 128: 983-989, 1982.
28. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
29. Los, M., Van de Craen, M., Penning, L. C., Schenk, H., Westendorp, M., Baeuerle, P. A., Droege, W., Krammer, P. H., Fiers, W., and Schulze-Osthoff, K. Requirement of an ICE/Ced-3 protease for Fas/APO-1-mediated apoptosis. Nature (Lond.), 375: 81-83, 1995.
30. Herr, I., Balemans, L., Boehler, T., Walczak, H., and Debatin, K-M. Monitoring of CD95 (APO-1/Fas) ligand expression in human T-cells by quantitative RT-PCR. Cell Death Differ., 3: 299-305, 1996.
31. Koopman, G., Reutelingsperger, C. P. M., Kuijten, G. A. M., Keehnen, R. M. J., Pals, S. T., and van Oers M. H. J. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood, 84: 1415-1420, 1994.
32. Dive, C., Gregory, C. D., Phipps, D. J., Evans, D. L., Milner, A. E., and Whyllie, A. H. Analysis and discrimination of necrosis and apoptosis (programmed cell death) by multiparameter flow cytometry. Biochim. Biophys. Acta, 1133: 275-285, 1992.
33. Kroemer, G., and Martinez-A., C. Pharmacological inhibition of programmed lymphocyte death. Immunol. Today, 15: 235-242, 1994.
34. McConkey, D. J., and Orrenius, S. Calcium and cyclosporin A in the regulation of apoptosis. Curr. Top. Microbiol. Immunol., 200: 95-105, 1995.
35. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., and Radinsky, R. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
36. Debatin, K-M. Cytotoxic drugs, programmed cell death and the immune system: defining new roles in an old play. J. Natl. Cancer Inst. (Bethesda), 89: 750-751, 1997.
37. Micheau, O., Solary, E., Hammann, A., Martin, F., and Dimanche-Boitrel, M-T. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J. Natl. Cancer Inst. (Bethesda), 89: 783-789, 1997.
38. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
39. Anel, A., Buferne, M., Boyer, C., Schmitt-Verhust, A-M., and Golstein, P. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. Eur. J. Immunol., 24: 2469-2476, 1994.
40. Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., Salvesen, G. S., and Dixit, V. M. Yama/CPP32β, a mammalian homolog of Ced-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell, 81: 801-809, 1995.
41. Kaufmann, S. H., Desnoyers, S., Ottaviano, Y., Davidson, N. E., and Poirier, G. G. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res., 53: 3976-3985, 1993.
42. Schulze-Osthoff, K., Bauer, M. K. A., Vogt, M., and Los, M. Role of ICE-related and other proteases in Fas-mediated apoptosis. Cell Death Differ., 3: 177-184, 1996.
43. Quan, L. T., Tewari, M., O'Rourke, K., Dixit, V., Snipas, S. J., Poirier, G. G., Ray, C., Pickup, D. J., and Salvesen, G. S. Proteolytic activation of the cell death protease Yama/CPP32 by granzyme B. Proc. Natl. Acad. Sci. USA, 93: 1972-1976, 1996.
44. Vogan, K., Bernstein, M., Leclerc, J-M., Brisson, L., Brossard, J., Brodeur, G. M., Pelletier, J., and Gros, P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res., 53: 5269-5273, 1993.
45. Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell, 82: 405-414, 1995.
46. Jaffrezou, J-P., Levade, T., Bettaieb, A., Andrieu, N., Bezombes, C., Maestre. N., Vermeersch, S., Rousse, A., and Laurent, G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J., 15: 2417-2424, 1996.
47. Cifone, M. G,. De Maria, R., Roncaioli, P., Rippo, M. R., Azuma, M., Lanier, L. L., Santoni, A., Testi, R. Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. J. Exp. Med., 177: 1547-1552, 1993.
48. Muller, C., Chatelut, E., Gualano, V., De Forni, M., Huguet, F., Attal, M., Canal, P., and Laurent, G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol., 32: 379-384, 1993.
49. Dominici, C., Petrucci, F., Caroli, S., Alimonti, A., Clerico, A., Castello, M. A. A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors. J. Clin. Oncol., 7: 100-107, 1989.
50. Mross, K., Bewermeier, P., Reifke, J., Kruger, W., Stockschlader, M., Zander, A., and Hossfeld, D. K. Pharmacokinetics of high-dose VP-16: 6-hour infusion versus 34-hour infusion. Bone Marrow Transplant., 13: 423-430, 1994.
51. Müller, M., Strand, S., Hug, H., Heinemann, E-M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest., 99: 403-413, 1997.